Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287–301.

Article  PubMed  Google Scholar 

Tokiwa S, Muto S, China T, Horie S. The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2011;15(4):539–45.

Article  CAS  PubMed  Google Scholar 

Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9(10):1323–6.

Article  CAS  PubMed  Google Scholar 

Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40(1):268–332.

Article  PubMed  Google Scholar 

Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020;21(4):667–78.

Article  PubMed  PubMed Central  Google Scholar 

Kidney Disease: Improving Global Outcomes AWG. KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD). Kidney Int. 2025;107(2S):S1–239.

Google Scholar 

Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–61.

Article  PubMed  PubMed Central  Google Scholar 

Reubi JC, Horisberger U, Studer UE, Waser B, Laissue JA. Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab. 1993;77(5):1323–8.

CAS  PubMed  Google Scholar 

Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334(4):246–54.

Article  CAS  PubMed  Google Scholar 

Parker E, Newby LJ, Sharpe CC, Rossetti S, Streets AJ, Harris PC, et al. Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system. Kidney Int. 2007;72(2):157–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makabe S, Manabe S, Kataoka H, Akihisa T, Yoshida R, Ushio Y, et al. Urinary aquaporin 2 as a potential indicator predicting tolvaptan response in patients with ADPKD. Kidney Int Rep. 2021;6(9):2436–44.

Article  PubMed  PubMed Central  Google Scholar 

Yamamoto M, Matsumoto R, Fukuoka H, Iguchi G, Takahashi M, Nishizawa H, et al. Prevalence of simple renal cysts in acromegaly. Intern Med. 2016;55(13):1685–90.

Article  PubMed  Google Scholar 

Fujio S, Takano K, Arimura H, Habu M, Bohara M, Hirano H, et al. Treatable glomerular hyperfiltration in patients with active acromegaly. Eur J Endocrinol. 2016;175(4):325–33.

Article  CAS  PubMed  Google Scholar 

Dullaart RP, Meijer S, Marbach P, Sluiter WJ. Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients. Eur J Clin Invest. 1992;22(7):494–502.

Article  CAS  PubMed  Google Scholar 

Fajfr R, Müller B, Diem P. Hypophyseal incidentaloma in a patient with autosomal dominant polycystic kidney disease. Praxis (Bern 1994). 2002;91((25–26)):1123–6.

Article  CAS  PubMed  Google Scholar 

Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005;68(1):206–16.

Article  CAS  PubMed  Google Scholar 

Kannabiran M, Singh V, Grewal S. Acromegaly presenting as psychotic disorder in a patient with familial autosomal dominant polycystic kidney disease. Ger J Psychiatry. 2006; 9:136–138.

Syro LV, Sundsbak JL, Scheithauer BW, Toledo RA, Camargo M, Heyer CM, et al. Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation. Pituitary. 2012;15(3):342–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mangaraj S, Patro D, Choudhury AK, Baliarsinha AK. A rare case of acromegaly and autosomal dominant polycystic kidney disease: case report and brief review of literature. AACE Clin Case Rep. 2019;5(5):e302–6.

Article  PubMed  PubMed Central  Google Scholar 

Otani D, Murakami T, Matsubara T, Hojo M, Nakae T, Moriyoshi K, et al. Acromegaly accompanied by diabetes mellitus and polycystic kidney disease. Endocr J. 2021;68(1):103–10.

Article  CAS  PubMed  Google Scholar 

Perico N, Ruggenenti P, Perna A, Caroli A, Trillini M, Sironi S, et al. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial. PLoS Med. 2019;16(4): e1002777.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D’Agnolo HMA, et al. Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial. JAMA. 2018;320(19):2010–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Griffiths J, Mills MT, Ong AC. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. BMJ Open. 2020;10(1): e032620.

Article  PubMed  PubMed Central  Google Scholar